How long does 5-MeO-DiBF last?

The total duration of 5-MeO-DiBF via oral is 4 hours to 6 hours. Peak effects last 30 minutes to 1 hour.

5-MeO-DiBF — SubstanceWiki

5-MeO-DiBF (5-methoxy-N,N-diisobutyl-2-aminobenzofuran), also described as a methoxybenzofuran analog of 5-MeO-DiPT, is a synthetic psychedelic compound belonging to the substituted benzofuran class rather than the classical tryptamine family. The compound's benzofuran core — a bicyclic ring system consisting of a benzene ring fused to a furan ring — structurally distinguishes it from tryptamines (which have an indole core), though the two classes share functional groups and appear to share serotonergic mechanisms.

5-MeO-DiBF represents an interesting structural bridge between the classical tryptamine psychedelics and the more unusual benzofuran class. It is hypothesized to act primarily through 5-HT1A and 5-HT2 receptor family agonism, consistent with other methoxy-substituted serotonergic compounds. The presence of the 5-methoxy group — shared with the highly potent 5-MeO-DMT — is a critical structural feature that strongly influences serotonin receptor binding and subjective character.

Community documentation of 5-MeO-DiBF is very sparse. It is one of the less commonly encountered research chemicals even within the benzofuran class. Its effects are characterized primarily through a small number of community experience reports and by structural extrapolation from related compounds. The diisobutyl N-substitution creates a molecule of substantial steric bulk, which may affect receptor binding and duration relative to the simpler 5-MeO analogs.

How It Feels

The onset of 5-MeO-DiBF is gradual and subtle, establishing itself over thirty to fifty minutes as a quiet shift in baseline consciousness. A mild warmth builds in the body, accompanied by a slight heaviness in the limbs and a faint tingling in the extremities. The mental effects are similarly understated: a gentle alteration of mood, a slight loosening of habitual thought patterns, and a growing sense of present-moment awareness that is pleasant but not dramatic.

As the experience develops over the next hour, the perceptual changes remain modest. Visual effects are minimal — perhaps a slight brightening of colors, a barely perceptible softening of edges, or an increased appreciation for visual detail that might be attributable as much to heightened attention as to pharmacological alteration. The primary effects are felt in the body and in the quality of consciousness rather than in dramatic perceptual distortions. There is a gentle mood elevation, a sense of calm wellbeing that settles over the experience like a light blanket. The body may feel slightly warmer and more relaxed than usual. Sounds are perceived with perhaps marginally greater clarity but without significant distortion.

The peak, arriving around sixty to ninety minutes and lasting one to two hours, is gentle by any psychedelic standard. The headspace is clear and functional — thought processes are subtly altered but not impaired. There may be a contemplative quality to thinking, a tendency toward reflection and introspection that is inviting rather than compulsive. Physical comfort is generally good, with mild relaxation and occasional waves of pleasant warmth. There is little to no visual geometry, no ego dissolution, and no challenging psychological material; the experience operates at a level of subtlety that might not be recognized as psychedelic by someone expecting more dramatic effects.

The comedown is smooth and gradual, the mild alterations fading over one to two hours. The total duration is three to five hours. There is very little residual effect, and the overall experience is best characterized as a gentle, exploratory nudge at the edges of psychedelic space. Given the limited number of experience reports available, individual responses may vary considerably, and what is described here represents a general impression drawn from sparse data rather than a well-established consensus.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(6)

Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(7)

Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...

Detection Methods

Urine Detection

5-MeO-DiBF is not targeted by standard immunoassay-based urine drug screens. 5-MeO-substituted tryptamines are metabolized primarily through hepatic pathways involving CYP2D6 and monoamine oxidase enzymes, producing demethylated and hydroxylated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect these metabolites in urine for approximately 24 to 48 hours after ingestion, though the detection window varies with dose and individual metabolic rate. The short duration of action of most 5-MeO tryptamines correlates with a relatively brief detection window.

Blood and Serum Detection

Blood detection windows for 5-MeO-DiBF are short, typically 2 to 8 hours after administration depending on the route. Smoked or insufflated routes produce rapid peak concentrations followed by swift clearance, while oral administration (particularly with MAO inhibition) extends both the effect and detection windows. LC-MS/MS is required for reliable blood quantification at the low nanogram-per-milliliter concentrations typical of 5-MeO tryptamines.

Standard Drug Panel Inclusion

5-MeO-DiBF is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. 5-MeO tryptamines do not cross-react with any standard immunoassay panel targets. There is no reliable cross-reactivity with amphetamine, opiate, or any other standard immunoassay. Detection requires a specific request for tryptamine testing at a laboratory with novel psychoactive substance capabilities.

Confirmatory Methods

Definitive identification of 5-MeO-DiBF requires LC-MS/MS or GC-MS analysis with compound-specific reference standards. Some forensic toxicology laboratories include 5-MeO-DMT in their expanded tryptamine panels, but coverage of other 5-MeO variants is less common. Bufotenin (5-HO-DMT), a metabolite of 5-MeO-DMT, may also be targeted. Quantitative analysis requires validated methods, as the structural similarity among 5-MeO tryptamines can complicate chromatographic separation without optimized conditions.

Reagent Testing (Harm Reduction)

The Ehrlich reagent produces a purple to violet reaction with 5-MeO-DiBF, confirming the presence of an indole ring characteristic of all tryptamines. This is the primary field identification tool and should always be the first test performed. The Hofmann reagent provides a confirmatory blue reaction. The Marquis reagent typically shows no reaction or a faint yellow to brown discoloration with 5-MeO tryptamines. Because 5-MeO tryptamines can be significantly more potent by weight than 4-substituted analogs, reagent testing alone is not sufficient for safe use. Quantitative analysis and accurate dosing are critically important for this subclass.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Limited Data

5-MeO-DiBF has extremely limited toxicological data available. The benzofuran scaffold is distinct from the tryptamine scaffold, and the toxicological assumptions applicable to tryptamines should not be uncritically extended to this compound.

Cardiovascular Concerns

The 5-methoxy group is associated with potent serotonergic activity, and 5-MeO compounds as a class can produce more pronounced cardiovascular effects (tachycardia, blood pressure elevation) than 4-substituted analogs. The benzofuran version shares this structural feature.

Psychological Risks

Given the 5-methoxy substitution — which in 5-MeO-DMT is associated with intense, occasionally overwhelming ego dissolution — caution is warranted even at moderate doses. The limited community experience with 5-MeO-DiBF means that dose-response relationships are poorly characterized.

Unknown Risks

The benzofuran scaffold introduces structural novelty relative to the well-characterized tryptamine class. The chronic toxicity and metabolic profile of benzofuran compounds is less well established than for tryptamines. Caution is accordingly amplified for this compound.

Addiction Potential

not habit-forming

Overdose Information

Fatal overdose from 5-MeO-DiBF alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.

However, psychological emergencies can occur and require appropriate response:

Severe anxiety, panic, or psychotic episodes
Dangerous behavior due to impaired reality testing
Self-harm in the context of a distressing experience

Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

5-MeO-DiBF

Quick Dosage

Dosage

oral

Duration

oral

How It Feels

Subjective Effects

Physical Effects

Physical(6)

Tactile(1)

Cognitive & Perceptual Effects

Visual(7)

Pharmacology

Benzofuran Scaffold vs. Tryptamine Scaffold

Serotonin Receptor Activity

Lack of Formal Data

Estimated Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Origins and Structural Context

Research Chemical Status

Contemporary Status

Harm Reduction

Extreme Caution Due to Limited Documentation

Dosing

Structural Novelty Caution

5-Methoxy Caution

Standard Protocol

Toxicity & Safety

Limited Data

Cardiovascular Concerns

Psychological Risks

Unknown Risks

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (5)

See Also

References (6)

Frequently Asked Questions

Cognitive(11)

Auditory(3)

Transpersonal(1)